Mô hình Sử dụng Chất gây Nghiện và Lịch sử Bị bắt giữ ở Người sử dụng thuốc liên quan đến HIV Nhập viện: Phân tích Lớp tiềm ẩn

Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81. Palepu A, Tyndall MW, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JSG. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32:522–6. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individual in the United States and Canada. PLoS ONE. 2013;8(12):e81355. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66. Kipp AM, Rebeiro PF, Shepherd BE, et al. Daily marijuana use is associated with missed clinic appointments among HIV-infected persons engaged in HIV care. AIDS Behav. 2017;[ePub ahead of print]. Qian H-Z, Mitchell VJ, Bebawy S, et al. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infect Dis. 2014;14:508. Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11. Howe CJ, Cole SR, Napravnik S, et al. The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV+ African Americans. AIDS Res Hum Retrovir. 2014;30(3):233–40. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–20. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50(1):93–9. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74. Schoenbaum EE, Lo Y, Floris-Moore M. Predictors of hospitalization for HIV-positive women and men drug users, 1996-2000. Public Health Rep. 2002;117(Suppl 1):S60–6. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44. Federal Bureau of Prisons. Inmate Statistics—Offenses. https://www.bop.gov/about/statistics/statistics_inmate_offenses.jsp. Accessed 30 Sept 2017. Carson EA. Prisoners in 2015. http://www.bjs.gov/content/pub/pdf/p14.pdf. Accessed 27 Apr 2017. Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725–31. Rozanova J, Brown S-E, Bhushan A, Marcus R, Altice FL. Effect of social relationships on antiretroviral medication adherence for people living with HIV and substance use disorders and transitioning from prison. Health Justice. 2015;3:18. Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70. Kranofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2nd ed. 2001. Skinner HA. The drug abuse screening test. Addict Behav. 1982;7(4):363–71. Derogatis LR, Fitzpatrick M. The SCL-90-R, the brief symptom inventory (BSI), and the BSI-18. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment: instruments for adults, vol 3. 3rd ed. Mahwah: Lawrence Erlbaum Associates Publishers; 2004. p. 1–41. Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94. Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535–69. Mplus Version 7.0 [computer program]. Version 7th. Los Angeles, California: Muthén & Muthén; 2012. Stata Statistical Software. Release 12 [computer program]. College Station: StataCorp LP; 2011. Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92(440):1375–86. Wang C-P, Hendricks Brown C, Bandeen-Roche K. Residual diagnostics for growth mixture models. J Am Stat Assoc. 2005;100(471):1054–76. Rubin DD. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94. Korthuis PT, Fiellin DA, McGinnis KA, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8. Reilly KH, Neaigus A, Wendel T, Marshall DM IV, Hagan H. Bisexual behavior among male injection drug users in New York City. AIDS Behav. 2016;20(2):405–16. CDC. HIV Surveillance Report, 2015; vol. 27. 2016; https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf. Accessed 23 Mar 2017. Lurigio AJ. The first 20 years of drug treatment courts: a brief description of their history and impact. Fed Probat. 2008;72(1):13–7. Tross S, Campbell AN, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of a NIDA Clinical Trials Network trial. J Acquir Immune Defic Syndr. 2008;48(5):581–9. Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7. Alemi F, Taxman F, Baghi H, Vang J, Thanner M, Doyon V. Costs and benefits of combining probation and substance abuse treatment. J Ment Health Policy Econ. 2006;9(2):57–70. Abraham AJ, O’Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder (SUD) treatment programs. J Subst Abuse Treat. 2014;44(1):120–5. Aletaris L, Roman PM. Provision of onsite HIV services in substance use disorder treatment programs: a longitudinal analysis. J Subst Abuse Treat. 2015;57:1–8. Feletcher BW, Lehman WEK, Wexler HK, Melnick G, Taxman FS, Young DW. Measuring collaboration and integration activities in criminal justice and substance abuse treatment agencies. Drug Alcohol Depend. 2009;103(Supplement 1):S54–64.